• Save
Global Regulatory Aspects
Upcoming SlideShare
Loading in...5
×
 

Global Regulatory Aspects

on

  • 1,815 views

 

Statistics

Views

Total Views
1,815
Views on SlideShare
1,815
Embed Views
0

Actions

Likes
5
Downloads
0
Comments
5

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
  • can you please mail me this presentation - avnsridhar@gmail.com
    Are you sure you want to
    Your message goes here
    Processing…
  • hi poonam
    kindly send me the above pptto my mail id zubair.spark@gmail.com.
    i hope u will.
    thank you.
    Are you sure you want to
    Your message goes here
    Processing…
  • I am unable to view the slides completely, they are cut at the sides and cant be downloaded either .

    Can anybody help with it
    Are you sure you want to
    Your message goes here
    Processing…
  • Thanks. May i know your professional introduction.!!
    Are you sure you want to
    Your message goes here
    Processing…
  • good Poonam
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Global Regulatory Aspects Global Regulatory Aspects Presentation Transcript

  • ElderGLOBAL REGULATORY ASPECTS By Poonam Bhardwaj JANUARY 2012 1
  • ElderWhere have the regulations come from?3,500 years ago ancient Egyptians were strict Rules of medicines were to be followed Reflected Quality, Safety & Efficacy Vigorously enforced Vi l f d If followed & patient died – absolution If b k & patient di d – d h penalty! broken i died death l ! 2
  • Elder REGULATORYRegulatory Affairs (RA)Regulatory Authority 3 View slide
  • Elder REGULATORY AFFAIRSThe Pharmaceutical Biotechnology and Pharmaceutical,Medical device, and Research &Development industries are most highlyregulated industries in the country. As India is growing very rapidly in thepharmaceutical sector, there is agrowing need of “Regulatory Affairs” to Regulatory Affairscater the current needs of industries forthe global competition competition. 4 View slide
  • REGULATORY TERRITORIES North America (US , Canada) Europe (Europe Union, Eastern Europe) Japan J Rest Of the World i.e. ROW(Asia Pacific Region, ANZ, LATAM, CEE, GCC, CIS) , ) 5
  • ElderREGULATORY TERRITORIESBusiness Boundaries are dissolving dissolving.The world pharmaceutical regulationsare in continues process ofharmonization.harmonization“Regulatory” is the key to enter into themarket of any Country. 6
  • ElderREGULATORY TERRITORIESBased on the “Economy” and Economy“Regulatory Control” of the countries,these are grouped into:Regulated M k tR l t d MarketsSemi Regulated MarketsNon Regulated Markets 7
  • ElderREGULATORY TERRITORIESBased on the “Economy” and Economy“Regulatory Control” of the countries,these are grouped into:Regulated M k tR l t d MarketsSemi Regulated / Emerging MarketsNon Regulated Markets 8
  • ElderREGULATORY TERRITORIESRegulated Markets US EU Japan ANZ (Australia, NewZealand) 9
  • ElderREGULATORY TERRITORIES European Union Member StatesAustria Greece NetherlandsBelgium Hungary NorwayBulgaria Iceland PolandCyprusC Ireland I l d Portugal P t lCzech Republic Italy RomaniaDenmark Latvia SlovakiaFinland Liechtenstein SloveniaEstonia Lithuania SpainFrance Luxembourg SwedenGermany Malta United Kingdom 10
  • ElderREGULATORY TERRITORIESEmerging Markets Asia Pacific ASEAN GCC (Gulf Co operation Council) Co-operation LATAM (Latin America) CEE (Central East Europe) CIS (Commonwealth Independent States) Africa Af i 11
  • Elder REGULATORY TERRITORIESREGION COUNTRIESAsia Pacific -- ASEAN Indonesia, Malaysia, Philippines, Singapore , Thailand, Brunei, Myanmar, Cambodia, Laos, Vietnam.GCC Bahrain, Kuwait, Oman, Qatar, Saudi Arabia,(Gulf Co-operation Council) and UAE.LATAM (Latin America) Brazil, Mexico, Venezuela Argentina, Chile, Columbia, Ecuador Guatemala, Barbados, BoliviaCEE (Central East Europe) Belarus, Bulgaria, Czech Republic, Hungary, Poland, Romania, Sl P l d R i Slovakia. kiCIS (Commonwealth Armenia, Azerbaijan, Belarus, Kazakhstan,Independent States) Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine Uzbekistan, Turkmenistan Ukraine, Uzbekistan GeorgiaAfrica South Africa, Ghana, Ethiopia, Kenya, 12 Tanzania, Luanda, Zambia, Sudan ..
  • Elder 13
  • ElderREGULATORY AUTHORITY Regulatory Agency Regulatory Body Regulatory Authority Government Body Health A th it H lth Authority 14
  • Elder REGULATORY AUTHORITYCountry Regulatory AuthorityArgentina National Administration of Drugs, Food & Medical Technology (ANMAT)Brazil Agência Nacional deVigilância Sanitária (ANVISA) National Health Surveillance AgencyBulgariaB l i Bulgarian D B l i Drug Agency (BDA) ACanada Health CanadaChina State Food and Drug Administration (SFDA) 15
  • Elder REGULATORY AUTHORITYCountry Regulatory AuthorityDenmark Danish Medicines AgencyEurope European Directorate for the Quality of Medicines and Healthcare (EDQM) & M di i dH l h European Medicines Agency (EMA)Germany Federal Institute for Drugs and Medical Devices (BfArM)India Central Drug Standard Control Organization (CDSCO) Food and Drug Administration (FDA) 16Ireland Irish Medicines Board
  • Elder REGULATORY AUTHORITYCountry Regulatory AuthorityItaly Italian Pharmaceutical AgencyJapan Pharmaceuticals and Medical Devices Safety Authority (PMDA)Netherlands Medicines Evaluation BoardNew Medsafe - Medicines and Medical DevicesZealand Safety AuthorityPakistanP ki t Drug C t l Organisation, Ministry of Health D Control O i ti Mi i t f H lth 17
  • Elder REGULATORY AUTHORITYCountry Regulatory AuthorityPhilippines Philippine Council for Health Research and Development (PCHRD)Poland Ministry of Health & Social WelfareSingapore Health Sciences Authority (HSA)Sri LankaS iL k Ministry f Healthcare and Nutrition Mi i t of H lth d N t itiSouth Africa Medicines Control Council (MCC) 18
  • Elder REGULATORY AUTHORITYCountry Regulatory AuthoritySwitzerland Swiss Agency for Therapeutic ProductsUganda National Council for Science and Technology (UNCST)UK Medicines and Healthcare Products Regulatory Agency (MHRA)USA The Food and Drug Administration (FDA)Yemen Ministry of Public Health and Population 19
  • Elder FDA Regulatory Pyramid US Laws L Congress Food, Drug & Cosmetic Act Regulations cGMP GLP = GxP 21 CFR Part 11; GCP 21 CFR Part 210, 211, 820, etc. Guidances Part 211. Current Good Manufacturing Practice for g Finished Pharmaceuticals. Standards GAMP 4 Guide; ISO 9000, IEEE Standards; ASTM Standards; USPharmacopeia (USP); International Conference on Harmonization (ICH) Slide 20
  • CFR = Code of US Federal Regulations Elder Title 26 Internal RevenueTitle 1 General Provisions Title 27 Alcohol, Tobacco Products and FirearmsTitle 2 [Reserved] Title 28 Judicial AdministrationTitle 3 The President Title 29 LaborTitle 4 Accounts Title 30 Mineral ResourcesTitle 5 Administrative Personnel Title Ti l 31 Money and Finance: Treasury M d Fi TTitle 6 [Reserved] Title 32 National DefenseTitle 7 Agriculture Title 33 Navigation and Navigable WatersTitle 8 Aliens and Nationality Title 34 EducationTitle 9 Animals and Animal Products Title 35 Panama CanalTitleTitl 10 Energy E Title 36 Parks, Forests, and Public PropertyTitle 11 Federal Elections Title 37 Patents, Trademarks, and CopyrightsTitle 12 Banks and Banking Title 38 Pensions, Bonuses, and Veterans ReliefTitle 13 Business Credit and Assistance Title 39 Postal ServiceTitle 14 Aeronautics and Space p Title 40 Protection of EnvironmentTitle 15 Commerce and Foreign Trade Title 41 Public Contracts and PropertyTitle 16 Commercial Practices ManagementTitle 17 Commodity and Securities Exchanges Title 42 Public HealthTitle 18 Conservation of Power and Water Title 43 Public Lands: InteriorResourcesR Title 44 Emergency Management and AssistanceTitle 19 Customs Duties Title 45 Public WelfareTitle 20 Employees Benefits Title 46 ShippingTitle 21 Food and Drugs Title 47 TelecommunicationTitle 22 Foreign Relations Title 48 Federal Acquisition Regulations SystemTitle 23 Highways Title 49 Transportation Title 50 Wildlife and Fisheries Slide 21Title 24 Housing and Urban DevelopmentTitle 25 Indians
  • Elder 21 CFR Part ……CFR Title 21 (Food and Drugs) g ) 1. General Enforcement Regulations 2. General Administrative Rulings and Decisions 3. Product Jurisdiction : 11. Electronic Records and Electronic Signatures : 58. G d L b 58 Good Laboratory Practice (GLP) t P ti : 210. Current Good Manufacturing Practice in Manufacturing Processing, packing, or Holding of Drugs. 211. Current Good Manufacturing Practice for Finished Pharmaceuticals. : 820. Quality System Regulation (QSR) Device GMP Slide 22
  • Elder ICHInternational Conference on Harmonisation ofTechnical Requirements for Registration of Pharmaceuticals 23
  • Elder ICH Bringing together theregulatory authorities and pharmaceutical industry of ………….??? 24
  • Elder ICHUSA Europe Japan 25
  • Elder Q S E M "Quality" "Safety" "Efficacy" "Multi- disciplinary disciplinary" Topics i.e. those Topics i.e. those Topics i.e. those Topics i.e. relating to relating to in relating to cross-cutting chemical and vitro and in vivo clinical studies Topics which pharmaceutical pre-clinical in human do not fit Quality studies subject (Dose uniquely into Assurance (Carcinogenicity Response one of the(Stability Testing, Testing Studies Good above Impurity Testing G t i it I it T ti Genotoxicity Clinical Cli i l categories t i etc) Testing etc.) Practices etc.) 26
  • Elder ICH - QualityICH section Description pQ1 Stability StudyQ2(R1) Validation of Analytical ProceduresQ3A(R2) Impurities in New Drug Substances p gQ3B(R2) Impurities in New Drug ProductsQ3C(R4) Impurities: Guideline for Residual SolventsQ4 PharmacopoeiasQ5 Quality of Biotechnological Products 27
  • Elder ICHICH section Description pQ6 SpecificationsQ7 Good Manufacturing Practice Guide for Active Pharmaceutical IngredientsQ8(R2) Pharmaceutical DevelopmentQ9 Quality Risk ManagementQ10 Pharmaceutical Quality SystemQ 11 Development and Manufacture of Drug Substances 28
  • ElderREGULATORY SUBMISSIONSNomenclature of Documents: DMF / ASMF (Drug Substance; DS) (D S b t Dossier (Drug Product; DP) 29
  • ElderREGULATORY SUBMISSIONSDrug Master File (DMF) is a master g ( )document containing complete informationon API.Drug Master File (DMF)Compilation for open and closed partIt is a submission of documents, coveringfactual and complete information onchemistry, stability, purity, i h i t t bilit it impurity profile, it filpackaging and cGMP status of any API. 30
  • ElderREGULATORY SUBMISSIONSDrug Dossier is a document which consist ofcomplete information of Drug product(Formulation). Viz: Information on API and Excipients Manufacturing process M f t i Quality documents Pre-clinical study P li i l t d Clinical Study 31
  • ElderOK I am Ready to File – No What? Now Its It CTD 32
  • ElderREGULATORY SUBMISSIONS WHAT IS CTD??? CTD (Common Technical Document) is an application FORMAT prescribed pp p organization of the information required to be submitted. A harmonized format for a regulatory dossier that is considered acceptable in US, Japan Europe and other regulatory also. l 33
  • Elder 34
  • ElderREGULATORY SUBMISSIONS TYPES OF CTD SUBMISSION PAPER SUBMISSION ELCTRONIC SUBMISSION (eCTD) 35
  • ElderPAPER SUBMISSION 36
  • ElderELECTRONIC SUBMISSION(e( CTD) 37
  • ElderRole of Regulatory AffairsProfessionals“Regulatory Affairs Professional ” is the crucial link between pharmaceutical company, its products and worldwide regulatory authorities viz. viz USFDA, EMEA, etc. 38
  • ElderREGULATORY AFFAIRS 39
  • ElderRole of Regulatory Affairs Professionals Regulatory Affairs Unit in a p g y pharmaceutical company p y is a vital unit that drives the R & D efforts of the company to the market successfully. A Regulatory Affairs department is a dynamic business unit which works with a focus to get products to the market with a commercially viable label in the least possible time and expenses. The world has become a global village and many companies are in a race to place many new products in the world markets to gain market share and increase earnings. 40
  • ElderRole of Regulatory Affairs Professionals In such a scenario a small delay in gaining market y g g access means huge loss in terms of market share and revenue generated. The key to success for pharmaceutical companies lies in obtaining timely marketing approval from regulators. regulators So to obtain timely marketing approval companies can either strengthen the regulatory department or outsource the same to regulatory affairs consulting firm. 41
  • ElderRole of Regulatory Affairs Professionals They ensure appropriate licensing, marketing and y pp p g, g legal compliance of pharmaceutical and medical products. They combine scientific knowledge, legal and business issues and co ordinate the approval and co-ordinate registration. 42
  • ElderRole of Regulatory Affairs Professionals 43
  • ElderIMPORTANT LINKS 44
  • ElderIMPORTANT LINKS 45
  • Elder IMPORTANT LINKShttp://www.fda.gov/default.htm 46
  • Elder IMPORTANT LINKShttp://www.edqm.eu/site/Homepage-http://www.edqm.eu/site/Homepage-628.htmlhttp://www.ema.europa.eu/ema/index.jsp?cu p p j p rl=pages/home/Home_Page.jsp&mid= rl=pages/home/Home_Page.jsp&mid= 47
  • Elder IMPORTANT LINKShttp://www.pmda.go.jp/english/index.htmlhttp://www pmda go jp/english/index html 48
  • ElderIMPORTANT LINKS http://www.cdsco.nic.in/http://www.drugscontrol.org/http://www drugscontrol org/ http://www.fda-mah.com/ 49
  • ElderCONCLUSION 50
  • Elder 51
  • Elder 52